Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24762017 | 0.86 | ALDH1A1 (0.60) | ALDH1A1TSHRPKMGAA | |
| SCHEMBL17680506 | 0.82 | ALDH1A1 (0.55) | ALDH1A1TSHRGAA | |
| SCHEMBL4948715 | 0.82 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNAPKMGAA | |
| SCHEMBL19450350 | 0.81 | GAA (0.54) | ALDH1A1LMNAPKMGAATBXA2R | |
| SCHEMBL4942519 | 0.80 | ALDH1A1 (0.56) | ALDH1A1TSHRPKMGAAHTT | |
| SCHEMBL5308838 | 0.79 | CA1 (0.50) | ALDH1A1GAARAB9A | |
| SCHEMBL15797966 | 0.78 | ALDH1A1 (0.65) | ALDH1A1TSHRLMNAPKMGAA | |
| SCHEMBL19450347 | 0.78 | SIGMAR1 (0.50) | ALDH1A1GAARAB9A | |
| SCHEMBL7395957 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TSHRPKMGAARAB9A | |
| SCHEMBL4942525 | 0.77 | ALDH1A1 (0.55) | ALDH1A1TSHRPKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921062-A2 | Amino acid derivatives as HIV aspartyl protease inhibitors | Ambrilia Biopharma Inc. (CA) | 2008-05-14 | — | — | EP | disclosed |
| EP-1458378-B1 | AMINO ACID DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060079550-A1 | Amino acid derivatives useful for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-6455587-B1 | AROMATIC SULFONYL DERIVATIVES | PHARMACOR INC. (CA) | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079550-A1 | Amino acid derivatives useful for the treatment of alzheimer's disease | BACE1, APP, PSEN1 | ALDH1A1 2554/4885TSHR 3263/4885LMNA 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.